Supplementary Table 3.

Treatment-Emergent Adverse Events by System Organ Class and Preferred Term: Preconditioning Phase, Safety Population

Variable	Placebo pretreatment (n = 26)	Vancomycin pretreatment (n = 32)
Subjects with at least 1 TEAE	3 (11.5)	4 (12.5)
Gastrointestinal disorders	2 (7.7)	3 (9.4)
Constipation	1 (3.8)	1 (3.1)
Diarrhea	1 (3.8)	1 (3.1)
Fecal incontinence	0	1 (3.1)
Flatulence	0	1 (3.1)
Infections and infestations	0	1 (3.1)
Candida infection	0	1 (3.1)
Musculoskeletal and connective tissue disorders	1 (3.8)	0
Back pain	1 (3.8)	0
Muscle spasms	1 (3.8)	0
Psychiatric disorders	1 (3.8)	0
Insomnia	1 (3.8)	0
Skin and subcutaneous tissue disorders	0	1 (3.1)
Rash	0	1 (3.1)

TEAE, treatment-emergent adverse event.